ECTS2013 Poster Presentations Cancer and bone: basic, translational and clinical (31 abstracts)
The DXA results in 41 patients with neuroendocrine tumors: a transversal study
Mara Carsote 1, , Andreea Geleriu 2 , Roxana Dusceac 2 , Roxana Miron 3 , Cristina Ene 2 , Valentin Radoi 1 , Gabriela Voicu 2 & Catalina Poiana 1,
1Davila UMPh, Bucharest, Romania; 2Parhon Institute, Bucharest, Romania; 3Constanta Hospital, Constanta, Romania.
Different results might be registered in DXA assessment in patients with neuroendocrine tumors (NET) since various factors induce bone disturbances as bone metastases, vitamin D hypovitaminosis, etc.
Aim: The analyze DXA in NET.
Material and method: The patients (p) were evaluated between 2008 and 2013. The diagnosis of NET was histological confirmed. We also included medullar thyroid cancer (MTC) with distance metastases and carcinoid syndrome. The WHO/ENETS classification was used for NET grading. The central DXA (GE Lunar device) was used. This is a pilot transversal study. The informed consent of the patients was obtained.
Results: 41 NET p were included: 24 women and 17 men. The mean age was: 56.5 years. The most frequent types of NET were: 44% G1, 27% G2 and 29% G3. The most frequent primary NET sites were: unknown 19%, lung 14% and MTC 13%. The mean time between NET confirmation and DXA was 14.54 months. The mean time in menopause (21 women) was 13.21 years. The mean DXA-BMD was in G1/G2/G3 NET groups were: 0.959/ 0.841/0.8 g/cm2.The student ttest between G1/G2 was P=0.1, respective G2/G3 P=0.1. The % of P with normal DXA/osteopenia/osteoporosis in G1/G2/G3 groups was: 45.5, 36.36, 18.18; 14.28, 71.42 and 14.28%; respective 16.66, 14.28 and 33.33. The mean BMD in women/men was: 0.88 / 0.9 g/cm2. The % of women with normal DXA/osteopenia/osteoporosis was: 33.33, 41.66, 25. 25% of men had normal DXA, and 75% of them had T-score lower than −1SD.
Discussions: A larger database will provide more information. NET is not included in general lists of bone loss causes.
Conclusion: The BMD decreased in the groups of NET from G1 (the best prognosis tumors) to G2 and then G3 NET (the most aggressive tumors). ¾ of women or men have low BMD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more